HOME >> BIOLOGY >> NEWS
Vascular access vital to pump up tissue engineering

Palo Alto, Calif.-- March 30, 2004 -- Pathbreaking developments in tissue engineering and regenerative therapies are facilitating the design and growth of new organs in labs using biopolymer scaffolds and matrices. Analysis of potential markets for tissue engineering reveals that basic problems such as vascularity must be solved before such implants can gain acceptance as standard treatment methods.

"When a matrix or scaffold containing cells is implanted into a patient to treat large bone defects or complex organ damage, it is difficult to ensure that the implanted tissue construct has sufficient vascular access," says Technical Insights Analyst Katherine Austin." A construct can be kept alive in a bioreactor by constantly supplying it with nutrients and oxygen, but once it is implanted in the patient, it has to be well supplied by capillaries. You have to have sufficient perfusion reaching all of the cells or they'll die."

Significant research is being carried out seeking means to overcome this barrier.

Desktop organ printing based on several 3D computer aided design (CAD) processes that can 'print' tissues layer by layer is another method being tested. The components of blood vessels are laid down within the various layers and the tissue constructs grow their own capillaries when the appropriate growth factors and cells are added.

Apart from this physiological issue, another major factor that hinders acceptance of breakthrough technologies of tissue engineering as standards of practice is the reluctance of the medical community to accept them.

Physicians and surgeons are often traditionalists, and unless they approve of and use them, the products are unlikely to succeed. In fact, lack of confidence among surgeons and inadequate marketing strategies have led several products from prominent companies to fail.

Such failures make investors cautious. Investor confidence in the technology is also low since it is still so
'"/>

Contact: Julia Paulson
jpaulson@frost.com
210-247-3870
Technical Insights
30-Mar-2004


Page: 1 2

Related biology news :

1. Vascular disease and aging
2. Vascular Surgeons Test New Treatment For Abdominal Aneurysms
3. Study Links Viruses And Vascular Diseases
4. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
5. Keep genome data freely accessible
6. Oxford Journals takes bold step towards free access to research
7. ORNLs nanobiosensor technology gives new access to living cells molecular processes
8. American Society of Plant Biologists offers developing nations free access to science journals
9. Open access to Ohio research
10. Open access initiative from the Company of Biologists
11. Unemployment, access to guns among factors that turn domestic violence deadly

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/2/2016)...   SoftServe , a global digital technology ... electrocardiogram (ECG) biosensor analysis system for continuous driver ... The smart system ensures device-to-device communication between ECG ... mobile devices to easily ,recognize, and monitor users ... technology advances, so too must the security systems ...
(Date:11/29/2016)... , November 29, 2016 Nearly one billion matches ... Reading ... DERMALOG ... of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... Opal ... provide essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, the ... FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard 204-pin SODIMM ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This single ... engineered to radically streamline culture processes, minimize processing time, significantly decrease production ...
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. ... discovers, develops and plans to commercialize innovative therapeutics ... of common stock were approved for trading on ... trading on the OTCQX, effective today, under the ... the OTCQX market, companies must meet high financial ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
Breaking Biology Technology:
Cached News: